In the modern era, treatment choice is guided by scientific evidence, usually gathered from well-conducted clinical trials, and often followed by the pooling of their data. In this article, we review the most recent pooled evidence regarding myocardial revascularization strategies and discuss how these meta-analyses have inherent shortcomings that should be better understood, prior to their purported conclusions potentially influencing clinical decisions.
In the modern era, treatment choice is guided by scientific evidence, usually gathered from well-conducted clinical trials, and often followed by the pooling of their data. In this article, we review the most recent pooled evidence regarding myocardial revascularization strategies and discuss how these meta-analyses have inherent shortcomings that should be better understood, prior to their purported conclusions potentially influencing clinical decisions.
Properly conducted randomized trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) can provide unbiased estimates of treatment effects. However, the design of such trials has often involved a primary outcome that is a composite measure and thus open to challenges with regard to the appropriate interpretation of each individual components [1] . Quantitative synthesis of such data from multiple trials can enable estimates of individual components of the composite outcomes (e.g. all-cause mortality). Where individual patient data are available, a full investigation of mediating effects, or subgroups analyses, may also be undertaken. Relevant to this article, we now have multiple meta-analyses of trials available [2] [3] [4] , which provide an opportunity to assess the appropriateness of criteria for patient selection between PCI and CABG. Consequently, we will appraise the robustness of these meta-analytic methods in answering the question at stake: does PCI provide equivalent results to CABG for the treatment of unprotected left main coronary artery stenosis and multivessel coronary artery disease?
NETWORK META-ANALYSES
Windecker et al. [4] summarized the data from trials of PCI or CABG which compared any combination of PCI with alternative PCI strategies (e.g. different drug-eluting stents), medical therapy or CABG, pooling 93 553 patients from 100 randomized trials in a network meta-analysis. The purpose of a network meta-analysis is to provide comparisons between all treatments which link through a chain of common comparators, whether or not there are randomized comparisons between them. Curiously, despite the choice of treatment to be most likely between 2 interventional strategies, the authors chose to describe the differences between intervention and medical therapy and did not report the difference between PCI and CABG. Of the significant findings on all-cause mortality, CABG reduced mortality with a rate ratio of 0.80 [95% confidence interval (CI) 0.70-0.91] when compared with medical therapy in the network analysis. The authors also found similar results in directly randomized trials. Among PCI treatments, only everolimus-eluting stents with a rate ratio of 0.75 (95% CI 0.59-0.96) and, marginally, zotarolimus eluting with a rate ratio of 0.65 (95% CI 0.42-1.00) showed evidence of superiority over medical therapy alone. These results were driven almost entirely by information derived from indirect comparison in trials that compared different PCI stents, with no direct comparison with CABG, and only one directly randomized comparison with medical therapy for everolimus-eluting stents, providing an underpowered relative risk of all-cause mortality of 0.33 (95% CI 0.03-3.16; P = 0.34).
The limitation of network meta-analyses is that they require the strong, generally unrealistic, assumption that treatment works in the same way in each trial included in the analysis. This assumption is not required for individual trials and individual patient meta-analyses.
INDIVIDUAL PATIENT META-ANALYSES
Individual patient meta-analyses are particularly useful, because (i) they can be used to examine treatment effects for consistency and (ii) strategies for the examination of subgroups are well established in the methodological literature [5] [6] [7] . The identification of true subgroups can be challenging. As Yusuf et al. [5] noted:
'A key principle for interpretation of subgroup results is that quantitative interactions (differences in degree) are much more likely than qualitative interactions (differences in kind). Quantitative interactions are likely to be truly present whether or not they are apparent, whereas apparent qualitative interactions should generally be disbelieved. . . .'
The key statistical tool to differentiate between true and chance differences in effect within subgroups is the test for interaction, which indicates whether the observed differences are of a magnitude which we would consider unlikely to have occurred by the play of chance. Within individual trials, such interaction tests are notoriously underpowered and may fail to identify real subgroup differences. This challenge may be overcome in individual patient meta-analyses. Indeed, regulatory agencies generally require an individual patient meta-analysis of all relevant trials to support the approval of an investigational medical product.
It is particularly welcome that an individual patient metaanalysis of 11 trials comparing PCI with CABG including some 11 518 patients, of whom 976 (8.5%) patients died, has recently been published [2] . The primary analysis from Head et al. [2] shows that CABG is superior to PCI, with PCI associated with a 20% increased relative risk of death (95% CI 6-37%; P = 0.004). The authors also undertook extensive testing of subgroups, and the principal ones are described in Fig. 1 .
In Fig. 1 , we observe that all the point estimates are greater than 1 (e.g. indicating numerical superiority of CABG), although many have wide CIs or are close to 1, thus showing no apparent convincing benefit. In this regard, if we drew a series of random subsets of the patients in the analysis by Head et al., we could find the play of chance expressed in the variation of the effects observed, as Richard Peto et al. famously did in ISIS-2 [8] . In that classic analysis, Peto et al. noted that patients with a star sign of Gemini or Libra appeared to experience increased mortality when taking aspirin but that a strong benefit was associated with aspirin for other star signs. Certainly, nobody believes that star sign affects the action of aspirin, and the test for interaction was non-significant, but this example provides a timely reminder that we must combine statistical rigour not only with biological plausibility but also with prospective definition of end points to separate true subgroups effects from the chance phenomena [5] .
Only the interaction between diabetes and outcome in Head et al. is nominally significant, with an at-first-glance impressive P-value of 0.008. However, as Yusuf et al. [5] note, it is important to consider both the plausibility and the questions of multiplicity. The latter are quite straightforward here: Head et al. likely performed many tests for interaction but highlighted these 10 as the principal ones (Fig. 1, excluding left main or multivessel disease) . Each test conducted at a critical P-value of 5% independently has a false-positive rate of 1 in 20. Indeed, each test is analogous to rolling a 20-sided dice, which has a tick on one side and a cross on 19 sides, so a good strategy for obtaining a tick on the dice is to roll it many times. Adjusting the P-value for multiplicity using a simple Bonferroni adjustment for the 10 tests ('rolls of the dice') provides an adjusted critical P-value of 0.005; in other words, diabetes does not achieve significance on the statistical criterion.
There are reasons to consider that patients with diabetes face increased risk with PCI [9] , and it could be construed that the benefits of treatment appear in the analysis to be numerically concentrated only in patients with diabetes. However, we do not also observe the difference in patients who have conditions related to diabetes such as prior myocardial infarction, hypertension, hypercholesterolaemia or peripheral vascular disease, highlighting the plausibility of the play of chance as an explanation for the effect observed. This inconsistency is further highlighted by an analysis previously conducted on a subset of the trial data in non-diabetic patients with multivessel disease, where Chang et al. [3] found a substantial benefit for CABG over PCI.
The number of patients randomized in the trials included in the analysis by Head et al. [2] is impressive. However, in time-toevent analysis, the power is driven by the number of events (e.g. deaths) rather than the number of patients randomized (e.g. 'at risk of death'). As only 8.5% of randomized patients died during the relatively short follow-up (mean 3.8 years) reported in the analysis by Head et al., the data are not suitable for the estimation of subgroup effects.
Another important point highlighted in the article by Head et al. is the weak evidence in support of the use of the SYNTAX score for the stratification of patients. In the analysis by Head et al., no significant treatment interaction with the 3 SYNTAX subgroups was demonstrated. Although the effects of treatment appear to increase with an increase in the subgroup score, the test for interaction shows that these apparent differences are not more than we would expect to see by chance alone (P = 0.21). In this situation, Yusuf et al. [5] correctly remind us that we should favour the primary outcome of the analysis. To identify whether any interaction truly exists, we need more events. Although these could be gleaned from new randomized trials, a more efficient approach (and more relevant given the decision problem and the longer term experience of patients) would be to enhance follow-up of the existing trial populations. This strategy should be pursued with some urgency and must be viewed as an important priority for the entire cardiovascular community.
Finally, a curious aspect in the article by Head et al. is that they separate left main disease and multivessel disease, providing estimates within each subgroup but do not report a test for interaction. Calculating the interaction test from the results provided by Head et al. [2] reveals a nominal P-value of 0.12, indicating that this interesting comparison, in fact, does not constitute a true subgroup effect (Fig. 1) .
IMPLICATIONS FOR CLINICAL PRACTICE
Evidence from clinical trials and meta-analysis is summarized in clinical guidelines, which provide a guide for the treatment of patient groups with similar characteristics. The treatment of the individual patient with coronary artery disease is, however, decided within the individual Heart Teams who take into account several factors including local expertise and facilities, clinical outcomes and the patient's preference. How should the patient level meta-analysis by Head et al. [2] and other recent evidences [3, 4] influence existing guidelines?
Although the work by Windecker et al. [4] provides convincing evidence that CABG is superior to medical treatment of coronary artery disease as described above, the work by Head et al. [2] demonstrates the superiority of CABG over PCI on all-cause mortality. The results of the primary analysis describe a substantial increase in mortality with PCI [hazard ratio (HR) 1.20; 95% CI 1.06-1.37, P = 0.004] detectable at a medium term follow-up (mean 3.8 years).
The next question is whether, in providing recommendations for treatment, we can identify subgroups of patients in whom the benefit of CABG over PCI varies.
SYNTAX SCORE
The previous guidelines [10] divided patients on the basis of coronary anatomy complexity using the SYNTAX score.
Although this has become an established algorithm in common practice, it is not underpinned by robust scientific evidence. No trial has used the SYNTAX score as a prospectively declared primary or secondary outcome. Head et al. [2] found no significant interaction between the SYNTAX scores. Thus, based on the current evidence, CABG should be inferred to achieve better results than PCI in all patients regardless of SYNTAX score. This conclusion applies both to multivessel disease and left main disease. 
MULTIVESSEL DISEASE AND LEFT MAIN DISEASE
Head et al. [2] provide an opportunity to compare the treatment of left main stenosis (LMS) with that of patients with multivessel disease, although no statistical comparison was described in the article precluding robust interpretation of these results. Fortunately, data provided in the article allow the comparison of the treatment effects in these 2 groups, with a non-significant value of P = 0.12 for interaction, and hence, for the LMS subgroup, we should infer the primary end point and a substantial disadvantage of PCI (HR 1.20, 95% CI 1.06-1.37, P = 0.004). On this point, the conclusions by Head et al. [2] offered in their article are scientifically questionable and should be reconsidered.
Limitations
The limitations of the current evidence, however, remain in 2 areas.
First, the end point in the study by Head et al. is all-cause mortality. However, we also know that complications that may affect the quality of life are important determinants in decision making for the individual patient's treatment.
Second, the number of events, on which these analyses are based, remains low, and this invites caution. More accurate follow-up data are required to utilize the very valuable information presented in the study by Head et al. with more scientific weight.
CONCLUSIONS
To conclude, based on the current evidence, CABG achieves better results than PCI in the treatment of coronary disease independently from the SYNTAX score and the presence of left main or multivessel disease. Although longer-term data are needed, at this moment, surgery should be considered the best therapeutic option in these settings among patients considered candidates for either procedure.
The recent evidence on CABG versus PCI provides an opportunity to rethink the way clinical guidelines and recommendations are made to guide the best treatment.
The finding that SYNTAX score grouping is not supported by the scientific evidence poses some challenges and invites a novel way of thinking and a break from the past. Although with insufficient events for subgroup analyses, these new data describe a substantial and convincing statistically significant mortality benefit of CABG over PCI. Previous studies have suggested that this difference is driven by a reduction in cardiovascular deaths, a more appropriate outcome to evaluate differences in treatments, and in the SYNTAX Trial, PCI had a higher cardiovascular mortality than CABG [11] . This finding demonstrates that CABG remains the gold standard treatment for coronary disease. These findings are applicable to patients with a low or acceptable risk for surgery, and individual patient treatment should be decided upon by the heart team's approach.
An evolving area within guidelines has been the treatment of left main disease. The recent evidence suggests a significant superiority of CABG over PCI irrespective of coronary anatomy, and there is no good evidence at this stage to suggest equivalence of PCI with CABG in this subgroup of patients [2] .
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